Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients.

Frontiers in immunology·2026

Same author

Validation of the Japan Society of Clinical Chemistry (JSCC) recommended reference measurement procedure for glycated albumin determination.

Annals of clinical biochemistry·2025

Same author

Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.

Frontiers in immunology·2025

Same author

Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer.

Cancers·2025

Same author

Peritoneal Dissemination and Malignant Ascites in Duodenal Cancer Successfully Treated With Adoptive Cell Therapy Using WT1- and MUC1-Pulsed Dendritic Cells and Activated T Cells With No Adverse Effects: A Case Report.

Cureus·2024

Same author

Diaphragmatic Nerve Paralysis After Redo Aortic Valve Replacement That Improved Over Time and Led to Successful Ventilator Weaning: A Case Report.

Cureus·2024

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Protocol for Long Duration Whole Body Hyperthermia in Mice

Protocol for Long Duration Whole Body Hyperthermia in Mice

Published on: August 25, 2012

[Hyperthermic immuno-cellular therapy-basic and clinical study].

Tsutomu Takeda¹, Kanae Fukunaga, Kenki Miyazawa

¹Osaka Cancer Immuno-Chemotherapy Center, Keisenkai.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|December 25, 2008

Summary

This summary is machine-generated.

Combination therapy using hyperthermia and activated lymphocytes shows synergistic effects in reducing tumor growth and metastasis in mice. Clinical trials suggest this approach offers significant benefits for cancer patients.

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Related Experiment Videos

Last Updated: Jun 26, 2026

Protocol for Long Duration Whole Body Hyperthermia in Mice

Protocol for Long Duration Whole Body Hyperthermia in Mice

Published on: August 25, 2012

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Area of Science:

Oncology
Immunotherapy
Therapeutic Hypothermia

Background:

Tumor growth and metastasis remain significant challenges in cancer treatment.
Hyperthermia and cellular immunotherapies are explored as potential cancer treatments.
Synergistic effects of combined therapies are being investigated to improve outcomes.

Purpose of the Study:

To evaluate the efficacy of hyperthermia and activated lymphocytes therapy in reducing tumor growth and metastasis.
To investigate the synergistic effects of combining hyperthermia with cellular immunotherapies (activated lymphocytes and dendritic cells) in preclinical and clinical settings.
To assess the clinical benefits and response rates in cancer patients receiving combination therapies.

Main Methods:

Basic research involved treating LLC tumor-bearing mice with hyperthermia or activated lymphocytes.
Clinical study included 526 cancer patients undergoing hyperthermia or immunotherapy.
Combination therapies involved hyperthermia with activated lymphocytes or dendritic cell therapy.

Main Results:

Both hyperthermia and activated lymphocytes therapy reduced tumor growth and lung metastasis in mice.
Combination therapy demonstrated synergistic effects, leading to greater reductions in tumor growth and metastasis.
Clinical outcomes showed 67 cases of benefit, including 8 complete responses, in patients receiving hyperthermia or immunotherapy.

Conclusions:

Hyperthermia and activated lymphocytes therapy are effective in controlling tumor progression and metastasis.
Combining hyperthermia with cellular immunotherapy offers synergistic benefits for cancer treatment.
The findings support the clinical effectiveness of combined hyperthermia and cellular immunotherapy for cancer patients.